MBCProject_0217_T2_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.660
- XENOBIOTIC_METABOLISM+0.660
- FATTY_ACID_METABOLISM+0.600
- OXIDATIVE_PHOSPHORYLATION+0.460
- PEROXISOME+0.430
- ADIPOGENESIS+0.420
- PANCREAS_BETA_CELLS+0.420
- COAGULATION+0.410
- KRAS_SIGNALING_DN+0.320
- CHOLESTEROL_HOMEOSTASIS+0.280
Top 10 suppressed
- G2M_CHECKPOINT-0.570
- E2F_TARGETS-0.560
- MITOTIC_SPINDLE-0.510
- MYC_TARGETS_V1-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.440
- PROTEIN_SECRETION-0.420
- DNA_REPAIR-0.390
- MYC_TARGETS_V2-0.380
- TGF_BETA_SIGNALING-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFE9-TTM4-A-1-1-R-A742-41 | — | C | 0.889 |
| 2 | TCGA-91-8496-01A-11R-2403-07 | — | cohortA1 | 0.841 |
| 3 | TCGA-67-3770-01A-01R-0946-07 | — | cohortA1 | 0.838 |
| 4 | SJEPD011_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.836 |
| 5 | SRR975601 | — | — | 0.820 |
| 6 | SRR5088896 | — | — | 0.813 |
| 7 | BS_B6M763JS | subependymal giant cell astrocytoma(SEGA) | — | 0.807 |
| 8 | AUR-AD9G-TTM2-A-1-1-R-A542-39 | — | C | 0.800 |
| 9 | TCGA-OR-A5J6-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.798 |
| 10 | SRR5088823 | — | — | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.660 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.660 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.600 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| PEROXISOME | 0.430 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.420 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |